Clinical Trials
214 trialsNCT06604442 2026-05-12
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics
Phase 4 Completed
NCT03934684 2026-05-11
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT04108208 2026-05-11
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT05457257 2026-04-21
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Active not recruiting
NCT00756509 2026-01-20
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
Phase 4 Completed
NCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT02625389 2025-10-10
A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Guerbet
Phase 4 Completed
NCT01496313 2025-10-03
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
Phase 4 Completed
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
NCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT05442554 2025-09-18
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Takeda
Phase 4 Completed
NCT05219162 2025-09-11
GPS
AstraZeneca
Phase 4 Completed
NCT01896479 2025-09-02
EXAMINER
Exelixis
Phase 4 Active not recruiting
NCT03715205 2025-08-29
Keynote-593
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT04513522 2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4 Completed
NCT04489888 2025-06-19
MK-3475-B10
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed
NCT03190330 2025-05-25
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Johnson & Johnson Private Limited
Phase 4 Completed
NCT04042376 2025-05-25
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Janssen Research & Development, LLC
Phase 4 Completed
NCT01673984 2025-05-23
GREAT
Ipsen
Phase 4 Terminated
NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT03641560 2025-04-08
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Phase 4 Completed
NCT02312960 2025-03-25
Radium-223 Dichloride Long-term Follow-up Program
Bayer
Phase 4 Completed
NCT04060654 2025-03-25
SUBLOCADE Rapid Initiation Extension Study
Indivior Inc.
Phase 4 Completed
NCT04330040 2025-03-10
SOLI
AstraZeneca
Phase 4 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT05741294 2025-02-20
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.
Phase 4 Completed
NCT02842749 2025-02-10
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Phase 4 Completed
NCT01804166 2025-02-04
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
Phase 4 Completed
NCT05848947 2025-01-29
MAApping
Sirtex Medical
Phase 4 Completed
NCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT03285763 2025-01-23
TAIL
Hoffmann-La Roche
Phase 4 Completed
NCT02274662 2025-01-16
Expanded Access Protocol Thymus Transplantation
Sumitomo Pharma Switzerland GmbH
Phase 4 Completed
NCT04526704 2024-12-30
PLX3397
Daiichi Sankyo
Phase 4 Completed
NCT04078152 2024-12-20
WAVE
AstraZeneca
Phase 4 Completed
NCT04541706 2024-12-20
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 4 Completed
NCT02918968 2024-12-09
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT01977651 2024-12-06
UPWARD
Astellas Pharma Inc
Phase 4 Completed
NCT02116582 2024-12-06
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT03035032 2024-11-26
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
NCT04825574 2024-11-26
Study for Patients Previously Treated in Avapritinib Clinical Trials
Blueprint Medicines Corporation
Phase 4 Completed
NCT04930536 2024-11-22
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
AstraZeneca
Phase 4 Completed
NCT03672643 2024-11-08
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
Pfizer
Phase 4 Terminated
NCT04416633 2024-11-08
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
AstraZeneca
Phase 4 Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT03301857 2024-05-20
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Amgen
Phase 4 Completed
NCT00942968 2024-04-18
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
Pfizer
Phase 4 Completed
NCT04511533 2024-04-05
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Pfizer
Phase 4 Completed
NCT03629886 2024-03-15
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
GlaxoSmithKline
Phase 4 Completed
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed